STOCK TITAN
  1. Home
  2. News
  3. CYTK

Cytokinetics Inc - CYTK STOCK NEWS

Welcome to our dedicated news page for Cytokinetics (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytokinetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytokinetics's position in the market.

News
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) announces positive topline results from SEQUOIA-HCM, a Phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy. Three Late Breaking Clinical Trial presentations at Heart Failure 2024 reveal insights on aficamten's efficacy, safety, and impact on exercise capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
clinical trial
-
News
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) presents positive 48-week data from FOREST-HCM study at ACC Scientific Session. Aficamten shows significant improvements in clinical efficacy endpoints, NYHA class, cardiac biomarkers, and cardiac structure and function for patients with obstructive HCM. Treatment results in sustained reductions in LVOT-G, improvements in symptoms, and biomarkers. Positive outcomes in NYHA Functional Class, NT-proBNP, cardiac structure, and SRT-eligibility. Well-tolerated with no treatment-related SAEs. LVEF reduction observed but manageable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
clinical trial
-
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) granted 78,000 stock options to new employees as a material inducement to their employment, with an exercise price of $70.11 per share. The options will vest over 4 years, subject to continued service, and have a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
News
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) announced that CEO Robert I. Blum will participate in a fireside chat at the Needham Virtual Healthcare Conference. The event will be live-streamed on the company's website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
conferences
-
News
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) announced four presentations at the ACC.24. The presentations cover various studies related to Hypertrophic Cardiomyopathy, including efficacy and safety of Aficamten, beta blocker use, standard of care medication patterns, and racial and ethnic differences in cardiovascular outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
-
News
Cytokinetics to Participate in March Investor Conferences
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) will be participating in several investor conferences in March 2024, including the Leerink Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and Barclays Annual Global Healthcare Conference. Key executives will be present for fireside chats and one-on-one meetings, providing opportunities for investors to engage with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) granted stock options to 3 new employees on February 29, 2024, totaling 28,500 shares at an exercise price of $72.24 per share. The options will vest over 4 years, with 1/4th vesting after a year and the rest monthly over 36 months. Each option has a 10-year term and is under the 2004 Equity Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
none
-
News
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) joins EURORDIS and NORD to support Rare Disease Day®, highlighting the global impact of rare diseases and the need for improved access to healthcare. The company reaffirms its commitment to health equity while progressing with regulatory submissions for aficamten in obstructive hypertrophic cardiomyopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
News
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
Rhea-AI Summary
Cytokinetics partners with The Mended Hearts, Inc. and WomenHeart to launch ENACT initiative aimed at increasing engagement in cardiovascular clinical trials among underrepresented groups. Grant funding provided to each organization to support patients in navigating the clinical trial process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
clinical trial
News
Cytokinetics Reports Fourth Quarter 2023 Financial Results
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) reported positive results from the SEQUOIA-HCM trial for aficamten, showing significant improvements in primary and secondary endpoints. The company plans to submit a New Drug Application to the FDA in Q3 2024. Financially, the company ended 2023 with a net loss of $526.2 million. Cash reserves stood at $655.4 million on December 31, 2023, excluding $83 million from stock sales in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
earnings
Stock CYTK logo
Cytokinetics Inc

Nasdaq:CYTK

CYTK Rankings

#985 Ranked by Market Cap
#3725 Ranked by Stock Gains
N/A Ranked by Dividends

CYTK Stock Data

7.48B
102.33M
0.57%
112.63%
12.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About CYTK

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.